Bio-Rad Labs (BIO) Tops Q1 EPS by 14c; maintains guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
This stock offers one of the most favorable long-term risk/rewards in biotech: RBC
May 8, 2024 4:30 PM EDTRBC Capital analysts highlighted one stock they believe has a favorable risk/reward in a note Wednesday.
The bank continues to view Bio-Rad Labs (NYSE: BIO) as one of the most compelling long-term investment opportunities in its coverage universe, emphasizing a favorable risk/reward profile.
Despite a 25%... More
Bio-Rad Labs (BIO) PT Lowered to $414 at RBC Capital
May 8, 2024 6:22 AM EDTRBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $414.00 (from $420.00) while maintaining a Outperform rating.
The analyst comments "We continue to view BIO as one of the most favorable long-term risk/reward names under coverage; though... More



